Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs).

Isogenica and Axxam collaborate to provide high-throughput in vitro screening assays in VHH antibody discovery

Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.